当前位置: 首页 > 详情页

Mutation-introduced dimerization of receptor tyrosine kinases: from protein structure aberrations to carcinogenesis

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Dept Mol Neuropathol, Beijing Neurosurg Inst, Beijing 100050, Peoples R China; [2]CGCG, Beijing 100050, Peoples R China; [3]Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [4]Beijing Inst Brain Disorders Brain Tumor Ctr, Beijing, Peoples R China; [5]Capital Med Univ, Dept Mol Neuropathol, Beijing Neurosurg Inst, 6 Tiantan Xili, Beijing 100050, Peoples R China
出处:
ISSN:

关键词: Receptor tyrosine kinases Mutation Dimerization Oncogenicity Gene rearrangement Protein structure alteration Oncogenesis

摘要:
Cancer is the greatest challenge to human health in our era. Perturbations of receptor tyrosine kinase (RTK) function contribute to a large chunk of cancer etiology. Current evidence supports that mutations in RTKs mediate receptor dimerization and result in ligand-independent kinase activity and tumorigenesis, indicating that mutation-introduced receptor dimerization is a critical component of oncogenesis RTK mutations. However, there are no specialized reviews of this important principle. In the current review, we discuss the physiological and harmless RTK function and subsequently examine mutation-introduced dimerization of RTKs and the role of these mutations in tumorigenesis. We also summarize the protein structure characteristics that are important for dimerization and introduce research methods and tools to predict and validate the existence of oncogenic mutations introduced by dimerization in RTKs.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
JCR分区:
出版当年[2013]版:
Q2 ONCOLOGY
最新[2023]版:

影响因子: 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者机构: [1]Capital Med Univ, Dept Mol Neuropathol, Beijing Neurosurg Inst, Beijing 100050, Peoples R China; [2]CGCG, Beijing 100050, Peoples R China;
通讯作者:
通讯机构: [1]Capital Med Univ, Dept Mol Neuropathol, Beijing Neurosurg Inst, Beijing 100050, Peoples R China; [2]CGCG, Beijing 100050, Peoples R China; [3]Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [4]Beijing Inst Brain Disorders Brain Tumor Ctr, Beijing, Peoples R China; [5]Capital Med Univ, Dept Mol Neuropathol, Beijing Neurosurg Inst, 6 Tiantan Xili, Beijing 100050, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:17009 今日访问量:0 总访问量:907 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院